In wake of un­ex­pect­ed pa­tient deaths, Macro­Gen­ics clos­es down PhII can­cer tri­al

Macro­Gen­ics is abrupt­ly shut­ting down a Phase II tri­al of its lead ex­per­i­men­tal drug af­ter sev­en pa­tients died in the tri­al.

All 62 pa­tients en­rolled in the tri­al had re­cur­rent or metasta­t­ic squa­mous cell car­ci­no­ma of the head and neck. They were split in­to two arms to test dif­fer­ent com­bi­na­tions of enobli­tuzum­ab, Macro­Gen­ics’ B7-H3-di­rect­ed an­ti­body, as a first-line treat­ment. Enobli­tuzum­ab was paired with ei­ther reti­fan­limab (an­ti-PD-1 an­ti­body) or tebote­limab (PD-1/LAG-3 bis­pe­cif­ic).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER